Multiple tumor marker elevation in androgen ablation-refractory prostate cancer with long-term response to metronomic chemotherapy: a case report

Franca Forni, Mariangela Massaccesi, Rocco Spagnuolo, Gabriella Macchia, Samantha Mignogna, Maria De Ninno, Numa Cellini, Bruno Giardina, Arnaldo Carbone, Alessio Giuseppe Morganti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Outcomes in hormone-refractory prostate cancer are very poor. The time from progression to death is only 12-19 months. We present the case of a 69-year-old man with hormone-refractory prostate cancer and bone metastases treated with metronomic chemotherapy (cyclophosphamide based). He had had a colon adenocarcinoma ten years before. The atypical features of this case were an unusually long-lasting response to metronomic chemotherapy and an increase in serum levels of some non-prostate-specific tumor markers (CEA and CA 19-9) that was not related to a relapse of colon cancer. We hypothesize a potential role of hypoxia inducing CA 19-9 and CEA expression in tumor cells, which may predict the development of progressive resistance to antiangiogenic therapies
Lingua originaleEnglish
pagine (da-a)243-247
Numero di pagine5
RivistaTHE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
Volume2010
Stato di pubblicazionePubblicato - 2010

Keywords

  • Cancer cells
  • chemotherapy
  • prostate
  • tumor marker

Fingerprint Entra nei temi di ricerca di 'Multiple tumor marker elevation in androgen ablation-refractory prostate cancer with long-term response to metronomic chemotherapy: a case report'. Insieme formano una fingerprint unica.

Cita questo